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ABSTRACT 
The constituent SH3, SH2, and kinase domains of the Abl kinase regulatory core can adopt 
an assembled (inactive) or a disassembled (active) conformation. We show that this assembly 
state strictly correlates with the conformation of the kinase activation loop induced by a total 
of 14 ATP site ligands, comprising all FDA-approved Bcr-Abl inhibiting drugs. The 
disassembly of the core by certain ligands can be explained by an induced push on the kinase 
N-lobe via A- and P-loop towards the SH3 domain. A similar sized P-loop motion is expected 
during nucleotide binding and release, which would be impeded in the assembled state, in 
agreement with its strongly reduced kinase activity. 
INTRODUCTION 
Abelson tyrosine kinase (Abl) plays a crucial role in many cellular processes such as 
proliferation, division, survival, DNA repair, migration and is an important cancer drug 
target.1-3 The regulatory core of Abl (Figure 1a) consists sequentially of the N-cap, the SH3 
and SH2 domains, and the kinase domain (KD) N- and C-lobes, which are separated by the 
catalytic cleft.4 This SH3-SH2-KD domain order is conserved among the Abl, Src, Csk, Brk, 
and Tec non-receptor tyrosine kinase families. Under physiological conditions, Abl is 
autoinhibited by interactions of the SH3 and SH2 domains with the KD N- and C-lobes, 
respectively, as well as by the docking of the myristoylated N-terminal glycine-2 (present in 
the Abl 1b splice variant) into a hydrophobic cavity of the KD C-lobe.4,5 This ‘assembled’ 
state of the Abl core is observed in crystal structures (Figure 1a)4,5 as well as in solution6,7 in 
the presence and absence of myristoylation. Similar assembled core structures have so far been 
observed for the Src8 and Btk9 kinases. 
Upon activation, the SH3 and SH2 domains disengage from the KD and are able to bind to 
cellular partners.2 The high activity of this ‘disassembled’ state may be explained by the 
readiness to form such intermolecular interactions, but also intramolecular interactions are 
involved. In particular, interactions between the Abl SH2 domain and the KD N-lobe have a 
critical role in leukemogenesis10 and enhance in vitro kinase activity11. Corresponding direct 
contacts between the SH2 domain and the top of the KD N-lobe have been observed under 
certain crystal4,10,12 and solution11,13 conditions, which may explain the enhanced activity by a 
modulation of the hinge motion between N- and C-lobes.14,15 
Abnormal reciprocal translocation between chromosomes 9 and 22 results in the 
deregulated fusion protein Bcr-Abl and subsequently in chronic myelogenous leukemia 
(CML).16 The ATP site inhibitors imatinib (Gleevec), nilotinib (Tasigna), and dasatinib 
(Sprycel) represent the front-line therapy against CML.17-19 However, spontaneous point 
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mutations render these inhibitors ineffective in a fraction of patients.18 In particular, the 
multidrug-resistant “gatekeeper” T334I mutation (Abl 1b numbering) has stimulated the 
search for new therapeutics.20,21 Among those are the ATP site inhibitors ponatinib (Iclusig)20 
and axitinib,22 as well as the allosteric inhibitor asciminib23 targeting the myristoyl binding 
pocket. The presumed mode of action of the latter is a stabilization of the autoinhibited, 
assembled state.7,24 Besides their efficacy against CML, inhibitors of Bcr-Abl are also widely 
used against Bcr-Abl-expressing subsets of B-cell leukemias, several diseases with Kit and 
Platelet-derived growth factor receptor (PDGF-R) aberrations,25 and have promising effects in 
cell and animal models of Parkinson’s disease.26,27 
Several structural motifs of the Abl KD are conserved in most kinases and crucial for the 
catalytic function (Figure 1c): the activation loop (A-loop) with the Asp-Phe-Gly (DFG) 
motif, the αC helix, and the glycine-rich (phosphate-binding loop) P-loop.28,29 The A-loop 
adopts two major conformations observed in most ligand complexes (Figure 1c,d and Figure 
S1).18 For type I inhibitors, the A-loop is in the ‘active’ (open) conformation positioned 
towards the αC helix (e.g. in the dasatinib complex)30 with the aspartate of the DFG oriented 
‘in’ or ‘flipped’ towards the ATP binding pocket. In contrast, type II inhibitors induce the 
‘inactive’ (closed) conformation of the A-loop, where the entire loop is rotated towards the P-
loop (e.g. imatinib complex) and the aspartate oriented ‘out’ from the ATP pocket.29 In this 
conformation, the central part of the A-loop mimics the bound substrate.31 Both the αC helix 
position12,28 and the P-loop conformation32 vary depending on the A-loop conformation and 
the interaction with the ligand. 
NMR RDC data on the Abl KD prove that in solution the A-loop predominantly (>85 %) 
adopts the same active conformation in a type I (dasatinib) complex and the same inactive 
conformation in type II (imatinib and nilotinib) complexes as observed in respective crystal 
structures.33 However, backbone 15N NMR relaxation data also indicate dynamics of the A-
loop in the nanosecond and microsecond regime, corresponding to exchange with minor 
conformations on the order of a few percent. Surprisingly, solution NMR and SAXS data on a 
larger Abl construct comprising the SH3-SH2-KD domains of the regulatory core show 
unequivocally that the core is in the assembled (autoinhibited) state in its apo form, but 
disassembles when the inhibitors imatinib or nilotinib bind (Figure 1b).7 As evident from 15N 
relaxation data, this disassembled, but inhibited state is characterized by a high nanosecond 
mobility of the SH3 and SH2 domains relative to the KD. So far, no crystal structures of such 
complexes have been obtained. The addition of the allosteric, myristoyl binding pocket 
inhibitor GNF5 to complexes of the Abl core with imatinib or nilotinib restores the assembled 
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state.7 Thus the allosteric inhibitor stabilizes the assembled state relative to the disassembled 
state induced by imatinib or nilotinib. 
Since imatinib and nilotinib induce the inactive A-loop conformation and at the same time 
disassemble the core, we hypothesized an allosteric coupling between the A-loop and the 
KD:SH3-SH2 interface and systematically investigated the conformations of the Abl 
regulatory core in complex with a total of 14 ATP site binding ligands. The results show that 
the inactive A-loop conformation induced by type II inhibitors leads to the disassembly of the 
core, whereas ATP site ligands with active A-loop conformations preserve the assembled core. 
An analysis of all available Abl crystal structures reveals that the type II inhibitors induce a 
small but consistently observed push of the KD N-lobe via the A-loop and the P-loop towards 
the SH3 domain. This push apparently destabilizes the KD:SH3-SH2 interface and causes the 
disassembly of the core. A mechanic model is proposed by which allosteric myristoyl binding 
pocket inhibitors relieve the exerted strain on the KD:SH3-SH2 interface by bending the αI’ 
helix and keeping the core in the assembled conformation. The detected allosteric link 
between A-loop, P-loop and core assembly state provides atomic details on the autoinhibition 
mechanism of the assembled state, since the hindrance of P-loop motions by the SH3 domain 
in the assembled state is expected to severely inhibit ATP binding and ADP release. 
RESULTS AND DISCUSSION 
The active and inactive A-loop conformations induced by type I and II inhibitors correlate 
strictly with the assembled and disassembled state of the regulatory core  
To carry out a comprehensive study of the assembled and disassembled state of the SH3-
SH2-KD Abl regulatory core (residues 83-534) in complex with ATP site ligands, we have 
obtained all commercially available ligands, for which Abl complex structures have been 
deposited in the PDB. This set of 14 ligands comprises all 5 FDA-approved Bcr-Abl inhibiting 
drugs, several drug candidates that are or were in clinical trials, as well as the ATP analogue 
AMP-PNP (Figure S2). The conformational state of the Abl regulatory core under solution 
conditions can be determined from characteristic NMR 1H-15N backbone chemical shifts of 
residues within the SH3 and SH2 domains.7 Figure 2a shows such characteristic shifts for 
residues V130, T136, G149 and V170 in the apo form and in complexes with the various ATP 
site ligands. As exemplified for V130, dasatinib, bosutinib, and AMP-PNP induce similar 
shifts as the apo form, corresponding to an assembled state, whereas imatinib, nilotinib, and 
ponatinib complexes exhibit shifted resonances corresponding to the disassembled state. 
A quantitative analysis of all the investigated complexes was carried out on all 1H-15N 
chemical shifts from the SH3 and SH2 domains. Chemical shift deviations Δδ relative to the 
apo form are shown in Figure 2b. Large deviations (Figure 2b, left) at many sites indicate the 
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disassembled state for imatinib, nilotinib, ponatinib, bafetinib, and rebastinib, whereas for all 
other cases (Figure 2b, right) only small deviations are observed corresponding to the 
assembled state. A numerical classification of these 1H-15N chemical shifts by Principal 
Component Analysis (PCA) yields a clear distinction between the assembled and disassembled 
conformations via the first principal component PC1 (Figure 2c, PC1 and PC2 explain 84 % 
of the data). 
We then asked whether PC1 correlates also to the A-loop conformation observed in 
various Abl complex structures. For this, the PDB was searched for entries with ≥ 90 % 
sequence similarity to the human Abl imatinib complex (2HYY) yielding a total of 51 
structures (Supplementary Table 1). No correlations are evident in these structures between 
the A-loop conformation and the crystallographic space groups or B-factors (Supplementary 
Table 1). However with no exception (Figure 2e), all type I ligand (Figure S2a) complexes 
with the characteristic active A-loop conformation (Cα distance G409-K375, d409/375 ≈ 12 Å) 
show chemical shifts corresponding to the assembled state (PC1 ≈ -0.1). In contrast, all type II 
ligand complexes (Figure S2b) with the inactive A-loop conformations (d409/375 ≈ 32 Å) 
induce the disassembled state (PC1 ≈ 0.2). Thus the A-loop conformation is directly correlated 
to the assembly state of the multidomain Abl core. 
Interestingly within the assembled conformations, PC2 further distinguishes the apo form 
and the AMP-PNP complex from the type I inhibitors (Figure 2C). An inspection of the 
corresponding chemical shift changes of the SH2 and SH3 domains indicates slight 
conformational rearrangements at their interfaces to the KD N- and C-lobes as well as at their 
mutual contact sites (Figure S3). Thus, type I inhibitors induce long-range interactions 
towards the SH2 and SH3 domain, which are different from those of the non-inhibited apo 
form and the AMP-PNP complex. 
The mechanism of core disassembly induced by type II inhibitors 
To identify the mechanism by which the inactive A-loop conformation induces the core 
disassembly, we aligned all 51 Abl structures on the KD C-lobe (Figure 3a). In all complex 
structures of KD-only constructs with type II ligands (inactive A-loop conformations, 
magenta), the KD N-lobe is slightly rotated by ~5-10˚ relative to KD complexes with type I 
ligands (active A-loop conformations, green) in the direction of the SH3 domain found in the 
full Abl regulatory core structures. The center of the rotation is located close to residue G340 
in the hinge between N- and C-lobe and the rotations induce ~2–5 Å displacements of residues 
facing the SH3 domain (e.g. K282) (Figure 3b). The reason for this movement of the N-lobe 
can be traced to steric interactions between the inhibitor, the A-loop and the P-loop (Figure 
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3c). As described previously,30 a steric clash between type II ligands and residues F401 and 
S404 prevents the A-loop from adopting the active conformation (green) and induces the 
inactive conformation (magenta). A-loop residues F401 and M407 in this inactive 
conformation would clash with residues Q271 and Y272 of the P-loop in the active 
conformation. As a result, the P-loop is pushed by 1-2 Å upward in the direction of the KD N-
terminus (e.g. V275 in Figure 3b) resulting in the overall 5-10˚ rotation of the N-lobe towards 
the SH3 domain. This conformation is further stabilized by π-π interactions between the ligand 
and the Y272, Y336 and F382 side chains32 as well as ion-pair interactions between A-loop 
residue R405 and residues E298/E301 at the N-terminal end of the αC helix (Figure S4a). In 
contrast, the active A-loop conformation is stabilized by a salt bridge between residue R405 
and residue E311 at the C-terminal end of the αC helix as well as two H-bonds between A-
loop residue S404 and residue I379 in the KD C-lobe (Figure S4b,c). 
In all solved structures of the complete assembled core, which comprise three 
independently deposited ternary complexes with PD166326 (type I) and myristic acid as well 
as one ternary complex with nilotinib (type II) and asciminib (Figure 3a,b yellow/orange and 
Figure S5), the N-lobe is positioned between the two conformations found for type I and type 
II ligand complexes of KD-only structures. Apparently, the presence of the SH3 domain 
confines the N-lobe to this intermediate position. Nevertheless, in the type II 
nilotinib/asciminib core structure, the N-lobe is rotated by about 5˚ more towards the SH3 
domain than in the type I PD166326/myristic acid core structures. 
A mechanical model of allosteric effects controlling core assembly 
All observations on the allosteric effects of ATP site and myristoyl binding pocket ligands 
onto the assembly state of the core can be rationalized by a simple mechanical model (Figure 
3d). In complexes of KD-only constructs with type II inhibitors the A-loop is pushed to the 
inactive conformation resulting in the rotation of the KD-N lobe towards the SH3 interface. In 
such constructs and in the absence of a suitable ligand in the myristoyl pocket, the C-terminal 
αI’ helix of the KD-C lobe is flexible in solution as evident from NMR.7,34 In KD crystal 
structures without myristoyl binding site ligands, this helix adopts a straight conformation, 
which would clash with the SH2 domain in the assembled core.5 We assume that albeit being 
flexible, helix αI’ also samples this clashing conformation to some extent in solution. The full 
Abl core in its apo form is assembled in solution and its KD-N lobe shows micro- to 
millisecond mobility as evidenced by NMR line broadening.7 In this state, the motion of αI’ 
must be restricted due to the steric hindrance by the SH2 domain. This results in a reduction of 
entropy and a higher free energy, i.e. a force directed, but not yet sufficient, to open the core. 
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Complexes of the core with type I inhibitors have very similar conformations as the assembled 
apo core. However, it is unclear whether type I inhibitors change the dynamical behavior of 
the KD N-lobe since not many residues could be observed in this region due to low NMR 
signal intensity. In complexes of the core with type II inhibitors, the KD N-lobe rigidifies7 and 
pushes towards the SH3 domain. This force acts synergistically with the force exerted by the 
flexible αI’ helix onto the SH2 domain and overcomes the forces holding the assembled core 
together. As a result, the core snaps open in a similar way as releasing a spring latch. Finally, 
in ternary complexes of the core with type II inhibitors and myristoyl binding pocket ligands, 
which bend helix αI’ away from the SH2 domain, the opening force is reduced and the core 
stays assembled.7 
For the clinical response to kinase inhibitors, besides molecular binding mode and its 
influence on the assembly state of the Abl core domains that are described here, additional 
mechanisms will certainly also contribute. These include the presence of Bcr-Abl tetramers in 
cells due to the N-terminal coiled-coil oligomerization domain35 and a yet to be explored 
possible overall structural difference due to different chromosomal translocation breakpoints 
that give rise to the two major Bcr-Abl protein isoforms p210 and p190. As recently 
demonstrated p210 and p190 have substantially different protein interactors and downstream 
signaling networks in leukemia cells36, which result in different kinase inhibitor sensitivities 
and possibly different clinical responses. 
Relating core assembly, A-loop/P-loop conformation and autoinhibition of kinase activity 
The role of the SH3 domain and the core assembly for Abl autoinhibition has been 
demonstrated in pioneering cellular assays where interactions between the SH3 domain and 
the linker to the KD had been abrogated by specific point mutations resulting in strongly 
enhanced kinase activity.37 Activity assays carried out on the SH3-SH2-KD, SH2-KD 
(residues 138-534) and a KD-only11 construct using the peptide substrate Abltide reproduce 
this strong autoinhibiting effect of the SH3 domain (Figure S6): e.g. the Michaelis-Menten 
vmax of the SH3-SH2-KD construct (assembled core in apo form) is about 4-fold (3-fold) 
reduced relative to the SH2-KD (KD-only) construct. 
The observed correlation between A-/P-loop conformation and the core assembly state 
gives new insight into this autoinhibition mechanism at the atomic scale. In complex structures 
of the Irk38 and Abl (Figure 3e)28 kinases with ATP analogues and peptide substrates, the A-
loop is in the active, open conformation, whereas the peptide substrate fills a similar position 
as part of the A-loop in the inactive, closed conformation.31 In these ternary complexes, the P-
loop tightly encloses the ATP molecule from the side of the N-lobe thereby fixing this part of 
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the catalytic center. This results in an N-lobe orientation, which is very similar to the ones 
observed in type I inhibitor complexes, but distinct from the type II complexes, where the 
hinge between N- and C-lobe is slightly more open (Figure 3e). It has been noted early on that 
in this conformation nucleotide entry or release must be strongly inhibited and that the 
opening of the catalytic cleft by a rotation of the N-lobe is the likely prerequisite for ADP 
release, which is the rate limiting step in many kinases.39 We can estimate from the solved 
ternary complexes that, in order to allow nucleotide binding or release, the P-loop must move 
by at least one atom layer (Figure 3e) in the direction of the SH3 domain of the fully 
assembled core. This movement will be very similar in size and direction as the one observed 
for the change between the active (type I inhibitor) and inactive (type II inhibitor) A-loop 
structures, e.g. a movement of P-loop residue V275 by 1.5 Å (van der Waals radius of oxygen) 
will induce a 7˚-rotation of the entire N-lobe around the hinge (G340) in the direction of the 
SH3 interface. This motion is possible in the disassembled regulatory core, but must be 
strongly hindered in the assembled core by the presence of the SH3 domain thereby reducing 
the speed of ATP binding and ADP release and hindering the catalytic reaction (Figure 3f). 
CONCLUSION 
In summary, we have shown a strict correlation between the A-loop conformation induced 
by ATP-binding pocket ligands and the overall assembly state of Abl’s regulatory core. All 
type I ligands, which leave the A-loop in the open, active state, keep the core assembled as in 
the apo conformation. In contrast, all type II ligands, which push the A-loop into the closed, 
inactive conformation, disassemble the core. The core opening can be rationalized by steric 
forces from the ligand via the A-loop and P-loop onto the kinase N-lobe towards the SH3 
domain. A simple mechanical model connects this mechanism to the stabilization of the 
assembled core by allosteric myristoyl binding pocket inhibitors, which reduce the pressure 
onto the KD:SH3-SH2 interface by bending helix αI’. 
The tight connection between A-/P-loop and core assembly state also provides high-
resolution insight into the autoinhibition mechanism, since it implies that the SH3 domain in 
the assembled state severely hinders the P-loop motion, which would be required for 
nucleotide binding and release. An identical inhibition mechanism is expected for all non-
receptor tyrosine kinases with an SH3-SH2-KD core. 
The autoinhibition by the assembled core constitutes only one of Abl’s regulation 
mechanisms. Interactions with cellular partners and phosphorylation provide further layers of 
regulation. In particular upon Abl activation, the activation loop gets phosphorylated at 
Y412,40,41 which stabilizes the open, active A-loop conformation.42 A second phosphorylation 
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site, Y245, is located in the SH2–kinase linker. Phosphorylation of Y245 prevents assembly of 
the core2 and strongly enhances trans-phosphorylation of Y412 by a second Abl molecule,11 
whereas its mutation impairs Abl activation.40 The binding of type II inhibitors induces a 
disassembled, yet inhibited state. We have previously shown that in Ba/F3 cells, 
phosphorylation of residue Y245 in the SH2-KD linker7 increases for type II inhibitor 
concentrations close to IC50, presumably due to the disassembly of the core. This may serve as 
a priming mechanism for enhanced Abl activity after inhibitor washout, although no increased 
downstream signaling has been detected in cellular experiments.43 Nevertheless, the effects of 
inhibitor-induced Abl core opening should be carefully considered in all in vivo situations, 
since they are universal for all type II inhibitors. In particular, emerging Abl mutants with 
lower affinity for type II inhibitors will still undergo core opening in the bound form, which in 
combination with the changed on- or off-rates may alter the dynamic equilibrium of Abl 
regulation and subsequent cellular reactions, thereby providing routes to resistance. 
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Figure legends 
 
Figure 1. Conformations of the Abl regulatory core. (a) Crystal structure of the Abl 
regulatory core in complex with PD166326 and myristic acid (PDB ID: 2FO0). The SH3 
domain (blue), SH2 domain (yellow), SH2-kinase linker (red), A-loop (green), P-loop (green), 
KD N-lobe and KD C-lobe (KD-N, KD-C, sand) are shown as cartoon, the chemical structures 
of PD166326 and myristic acid as sticks. (b) One of the possible conformations derived from 
NMR and SAXS data of the Abl!imatinib complex.7 Both SH2 and SH3 domains are mobile 
on the nanosecond time scale (indicated by light blue arrows). Same color scheme as in a, 
except for the P- and A-loops, which are shown as magenta. (c) Superposition of KD crystal 
structures of imatinib (sand) and dasatinib (gray) complexes (PDB ID: 2HYY and 2GQG) 
shown as cartoons. A-loop and P-loop are shown as magenta in the imatinib and as green in 
the dasatinib complexes. Chemical structures of imatinib and dasatinib are shown as sticks (d) 
A-loop conformations in active and inactive orientations with the three conformations of the 
DFG motif out, in and flip. The PDB codes of the structures are indicated in Supplementary 
Table 1. The color code corresponds to the one of Figure 2c. 
 
Figure 2. Evidence of allosteric coupling between A-loop conformation and assembly 
state of the Abl
 
core. (a) Individual 1H-15N TROSY resonances of selected residues of the 
Abl core which show characteristic shifts for the assembled and disassembled state. 
Resonances are color-coded according to the different ATP site ligands indicated on the left. 
The positions of the residues are indicted as spheres within the Abl core structure (cartoon). 
(b) Averaged 1H and 15N chemical shift differences Δδ = (ΔδN
2/25 + ΔδHN
2)1/2 between the 
ATP site ligand complexes and the apo form of the Abl core in the region of the SH3 and SH2 
domains (residues 83-234). The disassembled and assembled complexes are shown on the left 
and right side, respectively. (c) The first two principal components (PC1 and PC2) of the SH3 
and SH2 domain chemical shifts of the various Abl core complexes and the apo form derived 
from PCA. Assembled and disassembled conformations cluster in two regions. (d) Schematic 
illustration of the assembled and disassembled core and the respective A-loop conformations. 
The distance d409/375 between the C
α atoms of G409 and K375 (solid spheres) is taken as an 
indication of the active and inactive A-loop conformation. (e) Correlation between PC1 and 
d409/375. The electron density for the G409 atom was absent in the crystal structures of the 
ponatinib and bafetinib complexes. However, adjacent residues indicate an inactive A-loop 
also for these complexes. 
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Figure 3. Mechanism of allosteric interaction regulating the conformations and activity 
of the Abl core. (a) Superposition of a representative subset of Abl crystal structures aligned 
on the KD C-lobe: KD-only structures with inactive A-loop conformations (type II inhibitors, 
see Supplementary Table 1, magenta), KD-only structures with active A-loop conformations 
(type I inhibitors, see Supplementary Table 1, green), SH3-SH2-KD structure (5MO4) in 
complex with the type II inhibitor nilotinib and the allosteric inhibitor asciminib (orange). For 
the latter, the Cα atoms of T259, V275, K282, E294, and E327 are indicated as spheres. (b) 
Positions of the Cα atoms of T259, V275, K282, E294, and E327 for all investigated 51 
structures (Supplementary Table 1) shown within their plane of closest distance. The color-
coding follows panel (a). The positions for three further SH3-SH2-KD structures in complex 
with the type I inhibitor PD166326 and myristic acid (1OPK, 1OPL, 2FO0) are depicted in 
yellow. (c) Superposition of A-loop and P-loop conformations in KD crystal structures of 
imatinib (2HYY, magenta) and dasatinib (2GQG, green). Regions of steric clashes are 
represented as dotted spheres on the imatinib structure. (d) Mechanical model explaining the 
allosteric coupling between A-loop and P-loop conformation, the flexibility of the αI’ helix, 
and the Abl core assembly state. Different assembly states are induced by type I (green) and II 
(magenta) inhibitors of the ATP-binding site and of allosteric myristoyl binding pocket 
inhibitors (light blue). Light blue arrows indicate mobile elements, red bars mechanical forces. 
(e) Structural evidence that nucleotide binding and release requires KD hinge opening. Left: 
KD structure in complex with ATP analogue and substrate (2G2F). A space-filling 
representation of the active site region is shown on the top. Right: superposition of KD 
complexes with ATP analogue and substrate (2G2F, blue) and with imatinib (1OPJ, red). The 
rotation of the N-lobe towards the SH3 interface is clearly visible for the imatinib complex, 
whereas for the ATP analogue-substrate complex the N-lobe has a similar orientation as in 
type I inhibitor complexes (see panel a). (f) model depiction of hinge motion required for 
nucleotide binding and release. The hinge motion is possible in the disassembled core, but 
strongly hindered in the assembled core. 
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EXPERIMENTAL SECTION 
 
Ligands. All ligands were purchased from commercial suppliers and used without further 
purification (Supplementary Table 2). Bosutinib was confirmed to be the correct isomer by 
solution NMR.44 
 
Protein expression and purification. The 83-534 fragment of Abl (Abl 1b numbering) was 
expressed in 15N-labeled form in E. coli strain BL21(DE3) and purified as described earlier7 
with a slight modification. After the ion exchange purification step with a Q-sepharose HP 
column (GE Healthcare), fractions containing Abl were pooled to a typical volume of 20 ml 
and about 10 µM protein concentration. To this 500 µl of 12 µM of Lambda protein 
phosphatase (LPP) were added and the final buffer conditions adjusted to 2 mM TCEP, 100 
mM NaCl, 1 mM MnCl2, 0.01% Brij 35, 50 mM Tris·HCl pH 8. After incubation at 4° C 
overnight, ESI-MS analysis showed a complete de-phosphorylation of the protein sample. All 
experiments were carried in this de-phosphorylated form, which significantly enhanced the 
stability of the NMR samples to several days even for the least stable apo state. The protein 
was then subjected to gel filtration on a 16/600 Superdex 200 column (GE Healthcare) for the 
final purification step as before.  
The 138-536 fragment of SH2-KD Abl (Abl 1b numbering) construct was expressed in E. 
coli strain BL21(DE3) and purified using the published protocol.11  
 
The plasmid 42934 containing pPET-PKR/PPase for Lambda protein phosphatase (LPP) 
was purchased from Addgene. PKR was removed by restriction digestion with NdeI and 
EcoRI resulting in a pPET-PPase. Bacterial cultures were grown in E. coli strain BL21(DE3) 
in LB medium at 25° C to an OD600 of 0.6 and the protein expression was induced by addition 
of 200 µM isopropyl-β-D-thiogalactopyranoside. The cultures were pelleted down after 16 h, 
and the cells were resuspended in lysis buffer [50 mM Tris·HCl (pH 7.8), 2 mM EDTA, 20% 
(vol/vol) glycerol] and lysed using a M-110L microfluidiser (Microfluidics) operating at 
12,000 psi. Lysates were cleared by centrifugation at 30,000 g. The supernatant was loaded on 
a Q-sepharose HP column (GE Healthcare) that was pre-equilibrated with buffer A [50 mM 
Tris·HCl pH 7.8, 2 mM EDTA]. The protein was eluted with a linear gradient of 0-100% 
buffer B [50 mM Tris·HCl pH 7.8, 2 mM EDTA, 200 mM NaCl] in 6 CV (column volume). 
Fractions containing LPP were pooled and adjusted to a final concentration of 500 mM NaCl. 
The solution was then applied to phenylsepharose column (GE Healthcare) and washed with 
buffer A [50mM Tris·HCl pH 7.8, 500 mM NaCl, 2 mM EDTA] followed by buffer B [50mM 
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Tris·HCl pH 7.8, 2 mM EDTA, 50 % (vol/vol) glycerol]. The flow through containing LPP 
was concentrated and subjected to gel filtration on a 26/60 Superdex 75 column (GE 
Healthcare) equilibrated with 50 mM Tris·HCl pH 7.8, 0.1 mM EDTA, 10 % (vol/vol) 
glycerol. All purification steps were performed at 4 °C. Fractions containing LPP were then 
put into a storage buffer [50mM Tris·HCl pH 7.8, 100 mM NaCl, 2 mM DTT, 0.01 % Brij35, 
100 mM EDTA, 100 mM MnCl2, 50 % (vol/vol) glycerol], snap frozen with liquid nitrogen 
and stored at -80 °C for further use. 
 
Mass Spectrometry. The purified protein samples were applied to a Jupiter (5 µ, 300 Å, 
157 µl) C4 reverse phase column (Phenomenex). The phosphorylation state of the protein 
were determined by ESI-TOF mass spectrometry (Bruker microTOF) using maximum entropy 
deconvolution. 
 
NMR Spectroscopy. As in our previous study7, the isotope-labeled SH3-SH2-KD Abl 
construct was typically concentrated to ~100 µM and 270 µl volume in 20 mM Tris·HCl (pH 
8.0), 100 mM NaCl, 2 mM EDTA, 2 mM TCEP, and 0.02% NaN3. Ligands pre-dissolved in 
DMSO were added in the ratio of 3:1 (ligand: protein). The used slightly higher pH relative to 
crystallographic studies on this construct (PDB entries 2FO0, 5MO4: pH 7.5; PDB entries 
1OPL, 1OPK: pH 7.0) provided higher stability in solution, presumably due to the larger offset 
from its pI 5.9. All NMR experiments were performed at 303 K on a Bruker AVANCE 900-
MHz spectrometer equipped with a TCI triple resonance cryoprobe. 1H-15N TROSY 
experiments were recorded with 224 (15N) × 1024 (1H) complex points and acquisition times 
of ~40 ms in both 15N and 1H dimensions. All data were processed with NMRPipe software 
package45 and analyzed with SPARKY.46 The principal component analysis of chemical shift 
variations was performed using MATLAB (Mathworks). 
 
Analysis of PDB structures. PDB structures were analyzed and displayed using the PyMOL 
Molecular Graphics System (Schrodinger, LLC) 
Supporting Information 
The Supporting Information is available free of charge on the ACS Publications website 
at DOI:XXX 
Supplementary Figures 1-6 showing further structural and enzymatic analyses of Abl 
inhibitor interactions (PDF) 
Supplementary Table 1-2 giving statistics of analyzed Abl crystal structures and 
commercial suppliers of inhibitors (XSLX) 
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